Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  T.RVX.W.A | RVXCF

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Recent & Breaking News (TSX:RVX)

Resverlogix In Active Discussions With The Kingdom of Morocco's Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone

GlobeNewswire November 1, 2021

Resverlogix to Participate in Leading Scientific Conferences

GlobeNewswire October 29, 2021

Resverlogix to Present at Upcoming Conferences

GlobeNewswire October 13, 2021

Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial

GlobeNewswire October 12, 2021

Study Demonstrates Resverlogix's Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus

GlobeNewswire September 13, 2021

InvestmentPitch Media Video Discusses Resverlogix and Report of its Apabetalone Drug Meeting Primary Endpoint in Pulmonary Arterial Hypertension Investigator Led Pilot Study - Video Available on

Newsfile September 9, 2021

Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study

GlobeNewswire September 8, 2021

Resverlogix Announces Management Change

GlobeNewswire July 6, 2021

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire June 24, 2021

Resverlogix Announces Voting Results from the 2021 Meeting of Shareholders

GlobeNewswire June 23, 2021

Resverlogix (TSX:RVX) partners with EVERSANA to launch COVID-19 treatment

Trevor Abes  June 3, 2021

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

GlobeNewswire June 3, 2021

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.

Newsfile May 21, 2021

Resverlogix Announces US$6 Million Debenture Financing

GlobeNewswire May 5, 2021

Resverlogix’s (TSX:RVX) apabetalone breaks new ground in chronic kidney disease treatment

Trevor Abes  April 27, 2021

Resverlogix's Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease

GlobeNewswire April 27, 2021

Zenith Epigenetics Announces Clinical Collaboration with Astellas

GlobeNewswire April 22, 2021

Apabetalone's Positive Impact on COVID-19 in Human Lung Cells Published in Biomedicines

GlobeNewswire April 20, 2021

Health Canada authorizes Resverlogix (TSX:RVX) to begin clinical studies of Apabetalone for COVID-19

John Ballem  April 12, 2021

Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19

GlobeNewswire April 12, 2021